AALL1231: A Phase III Randomized Trial Investigating Bortezomib (NSC# 681239; IND# 58443) on a Modified Augmented BFM (ABFM) Backbone in Newly Diagnosed T-Lymphoblastic Leukemia (T-ALL) and T-Lymphoblastic Lymphoma (T-LLy)

ID Number 80-0066-01231

Principal Investigator(s)
Birte Wistinghausen

Department(s) or Division(s)
Hematology and Medical Oncology


You are being asked to take part in this research study because you have been diagnosed with T-lymphoblastic leukemia (T-ALL) or T-Lymphoblastic Lymphoma (T-LLy)

This study is called a clinical trial.  A clinical trial is a research study involving treatment of a disease in human patients.  This study is organized by Children's Oncology Group (COG).  COG is an international research group that conducts clinical trials for children with cancer.

Contact Information
Dr Birte Wistinghausen
(212) 824-7309

Recruiting Patients: Yes